Equities

Shanghai Rendu Biotechnology Co Ltd

688193:SHH

Shanghai Rendu Biotechnology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)23.78
  • Today's Change-18.09 / -43.21%
  • Shares traded113.40k
  • 1 Year change-50.32%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai Rendu Biotechnology Co Ltd is a China-based company mainly engaged in the research, development and sales of molecular diagnostic reagents. The Company utilizes ribonucleic acid (RNA) isothermal amplification technology to provides multiple series of diagnostic reagents, including respiration series, reproduction series, enterovirus series, blood-borne diseases series and other diagnostic reagents. The Company also designs and manufactures medical instruments. The Company mainly sells its products within domestic market.

  • Revenue in CNY (TTM)177.96m
  • Net income in CNY21.27m
  • Incorporated2007
  • Employees358.00
  • Location
    Shanghai Rendu Biotechnology Co LtdF3 Block 7 #590 Ruiqing RdEast Zone, Zhangjiang High- Tech ParkShanghai 201201ChinaCHN
  • Phone+86 2 150720069
  • Fax+86 2 150720069
  • Websitehttp://www.rdbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanghai Rightongene Biotechnlgy Co Ltd249.02m-5.17m1.21bn501.00--1.28--4.84-0.0877-0.08774.4316.870.23841.201.32497,050.10-1.374.16-1.464.4972.9870.45-5.7511.6211.12--0.0255.90-39.142.84-80.41-11.4619.65--
AVE Science & Technology Co Ltd202.67m22.56m1.22bn492.0054.172.45--6.030.33180.33182.987.350.36831.9330.00411,925.304.107.214.468.1856.7358.9311.1315.485.51--0.0022.461.795.8819.81-4.62-23.68--
Jiangsu Nanfang Medical Co Ltd584.85m-167.99m1.29bn858.00--2.83--2.21-0.5812-0.58122.021.580.42941.863.49681,641.10-12.31-1.09-28.91-2.005.6420.14-28.66-1.910.3748-9.580.5314--10.034.57-906.35---3.18--
Suzhou Iron Technology Co Ltd323.32m-43.37m1.30bn680.00--1.73--4.01-0.5716-0.57164.249.720.23431.931.18475,466.10-3.407.11-5.4810.5646.2456.00-14.5219.171.23-4.900.257125.00-23.848.73-71.17-10.4036.50--
CareRay Digital Medical Technology CoLtd287.84m24.70m1.32bn252.0054.181.55--4.590.27690.27693.229.690.30621.603.921,142,221.002.626.652.857.3742.7641.178.5515.646.76--0.022427.6133.815.17374.05-20.7477.38--
Touchstone International Medi Sci Co Ltd274.03m56.95m1.53bn243.0025.732.67--5.570.7310.7313.517.050.43523.1618.941,127,699.009.0510.0910.0610.8255.9657.5920.7820.174.76--0.002824.669.3116.349.5315.39-2.39--
Thalys Medical Technology Group Corp1.90bn-210.78m1.65bn1.41k--1.55--0.8715-1.36-1.3611.685.310.55084.161.221,349,051.00-6.04-0.8933-11.27-1.6218.5122.12-10.97-1.491.43-0.96660.4974---13.108.77-2.69---19.20--
Shanghai Rendu Biotechnology Co Ltd177.96m21.27m1.67bn358.0078.731.81--9.410.53180.53184.4523.180.17341.292.41497,088.502.076.262.227.1779.8774.3611.9514.5412.02--0.00527.96-45.8918.85-64.60--23.48--
Guangzhou LBP Medicine Scnc&Tech Co Ltd495.46m32.09m1.89bn907.0059.141.48--3.810.34140.34145.2113.620.35942.011.98546,263.801.845.101.925.5566.9275.155.1212.977.74--0.010124.42-1.9910.18-6.18-8.21-2.98--
Guangzhou Jet Bio-Filtration Co Ltd524.26m70.98m2.04bn1.09k25.921.74--3.880.55980.55984.138.320.32463.304.08480,536.104.419.354.6810.3937.7136.7613.6017.897.825.330.233329.64-24.0617.42-60.34-8.0247.32--
Allgens Medical Technology Co Ltd191.19m5.11m2.28bn202.00483.351.61--11.940.03480.03481.4510.490.12511.322.81946,490.300.02327.620.02418.3073.8783.600.185539.0524.27--0.03335.25-7.6812.86-43.0410.46-26.12--
Data as of Sep 13 2024. Currency figures normalised to Shanghai Rendu Biotechnology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

3.37%Per cent of shares held by top holders
HolderShares% Held
Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2024154.85k1.89%
China Asset Management Co., Ltd.as of 30 Jun 202479.25k0.97%
Truvalue Asset Management Co. Ltd.as of 30 Jun 202413.00k0.16%
Fortune & Royal Asset Management Co., Ltd.as of 30 Jun 20248.12k0.10%
Gfund Management Co., Ltd.as of 30 Jun 20247.11k0.09%
China Universal Asset Management Co., Ltd.as of 30 Jun 20246.21k0.08%
Hongde Fund Management Co., Ltd.as of 30 Jun 20245.47k0.07%
ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 20241.60k0.02%
Minsheng Royal Fund Management Co., Ltd.as of 30 Jun 20241.000.00%
Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.